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Background: Heart failure is known to be associated with increased adverse clinical
outcomes in coronary artery diseases. The impact of percutaneous coronary inter-
vention (PCI) for chronic total occlusion (CTO) in patients (pts) with new onset heart
failure is not clear. We compared the 12-month clinical outcomes of pts treated by PCI
with optimal medical therapy (OMT) for CTO lesions in pts with new onset heart
failure.
Methods: A total of 458 consecutive CTO pts newly diagnosed with heart failure or
showing symptoms of heart failure (NYHA class 2 or CCS class 2) were divided
into 2 groups; one group underwent PCI (PCI group; n¼246) and the other group was
treated with OMT (OMT group; n¼212). Major clinical outcomes were compared
between the two groups up to 12 months.
Results: At baseline, the OMT group had a higher prevalence of elderly, cerebro-
vascular accidents, de novo lesion, left main disease, multivessel disease, multivessel
CTO, RCA-CTO, and abundant collaterals (grade 2), whereas the PCI group had a
higher prevalence of male gender, prior MI, prior PTCA and LAD-CTO lesions.
Clinical outcomes at 12 months were similar between the 2 groups except lower
mortality in the PCI group (Table). After baseline adjustment by multivariate analysis,
however, there was no difference between the 2 groups.
Conclusion: In our study, mechanical revascularization by PCI for CTO lesions in pts
with new onset heart failure as compared with OMT seems to have no beneﬁt in
reducing 12-month mortality. Long-term follow up with a larger study population will
be necessary for further determination.P
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Comparison in Cardiac Remodeling Between Surgical Treatment and Device
Closure of Atrial Septal Defect
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Background: Atrial septal defect (ASD) is the 2nd most common congenital heart
anomaly in adults. As treatment options, there are operative ASD closure (Surgery)
and percutaneous device closure (Device). The aim of this study was to elucidate the
cardiac remodeling after ASD closure and to compare the effects of Surgery and
Device in similar ASD size.
Methods: Among patients who underwent ASD closure in Catholic medical school,
St. Vincent’s Hospital from January 2004 to December 2012, 28 patients were
enrolled. Transthoracic echocardiography (TTE) was performed before and after
correction of the ASD in both Surgery and Device groups.
Results: Although therewere signiﬁcant differences in age andASD size in both groups,
after closing ASD, LV dimension increased in both groups, on the other hand, decrease
in right atrium volume (RAVol) and maximum regurgitation velocity of tricuspid valve
(TR Vmax) was noted. Aortic diameter and LV ejection fraction increased in Surgery
group. Further subgroup analysiswithASD size of 13 to 24mmwas analyzed to compare
differences in cardiac remodeling between the two groups. There were coherent results
of increase of LV dimension and reduction of TR Vmax and RAVol in both subgroups.
However, RAVol reduction was more remarkable in Surgery than Device subgroup.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/POSTConclusion: Although there was difference in baseline parameters between two
groups, which may have affected the choice of treatment option, the parameters
measured by TTE showed signiﬁcant change in structural cardiac remodeling. By
subgroup analysis regarding to ASD size, showed consistent improvements in cardiac
geometry without signiﬁcant difference between the groups. In conclusion, in selected
cases of ASD, it is reasonable to treat percutaneously considering complication
occurrence, post-procedural recovery, and hospital stay.Drug-eluting Stents
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Background: A novel dual therapy stent (DTS) may improve clinical outcome due to
a combination of sirolimus drug elution and endothelial progenitor cell technology for
reduced restenosis and accelerated endothelisation. However clinical data remains
limited on the use of this novel technology. We aim to report on the use of a novel
DTS device in our centre.
Methods: All patients who underwent PCI with the ComboR DTS in our centre were
enrolled. All patients underwent diagnostic angiograms and PCI according to guide-
line recommended indications and techniques. Baseline clinical and angiographic
characteristics were collected. Clinical outcomes for MACE at 6 and 12 months were
studied.
Results: Fifty three patients (83% male) of mean age 61.42 +/- 11.63 years were
studied. 15.1% (n¼ 8), 24.5% (n¼ 13) and 60.4% (n¼ 32) were admitted for STEMI,
ACS and Stable angina respectively. The prevalence of hypertension, hyperlipidaemia
and diabetes mellitus were 88.7% (n¼47), 75.5% (n¼ 40) and 50.9% (n¼ 27)
respectively. 12.7% (n¼ 7) had left main disease and 41.8% (n¼ 23) had triple vessel
disease. 69 ComboR DTS with a mean diameter of 3.06 +/- 0.35 mm and a mean
length of 22.07 +/- 5.55 mm were implanted. 50.7% (n¼ 35), 11.6% (n¼ 8) and
39.0% (n¼ 20) were implanted in the LAD, LCx and RCA respectively. 4.3% (n¼ 3)
were deployed in the left main artery and in bypass grafts respectively. There were
10.1% (n¼9), 69.6% (n¼48) and 20.3% (n¼ 14) ACC/ AHA angiographic type A, B
and C lesions. 6 (8.7%) and 7 (10.1%) were CTO and bifurcation lesions respectively.
Angiographic success rate was 100%. There were no cases of stent thrombosis or
inhospital mortality.
Conclusion: The use of ComboR DTS was associated with excellent angiographic and
short term clinical outcome in this study. We plan to report on 6 month clinical
outcomes at the time of presentation.TCTAP A-167
Bioabsorbable Vascular Scaffolds (BVS) Eluting with Everolimus: for
Percutaneous Coronary Intervention (PCI) of Patients with De-novo Coronary
Artery Lesion: Our Experiences at Apollo Hospitals Dhaka
Shams Munwar, Ahm Waliul Islam, Shahbudin Talukder, A. Q. M. Reza,
Tamzeed Ahmed, Azfar H. Bhuiyan, Rowsan Masud, Atique B. Siddique
Apollo Hospitals Dhaka, Dhaka, Bangladesh
Background: Aim of the study was to evaluate the primary procedural success of
percutaneous coronary intervention (PCI) of de-novo coronary artery lesion by using
BVS Absorb stents eluting with Everolimus.
Methods: Total 16 patients were enrolled in this very preliminary study of BVS
absorb. Among them, Male: 11 and Female: 5. Total 20 stents were deployed. Mean
age were for Male: 56 yrs, for Female: 60 yrs. Associated CAD risk factors were
Dyslipidemia, High Blood pressure, Diabetes Mellitus, Positive FH for CAD and
Smoking (all male).
Results: Among the study group; 13 (81%) were Dyslipidemic, 10(62.5%) were
hypertensive; 6 (37.5%) patients were Diabetic, FH 3(18.75%), and 2(18%) were
all male smoker. Female patients were more obese (BMI M 25: F 27) and
developed CAD in advance age. A common stented territory was for LAD: 6
(37.5%), LCX 5 (25%), RCA 6(37.5%). One patient had both LCX and LAD
stenting. Total 3 patients had double/overlapping stent in RCA lesion. Territory
wise distributions of BVS Absorb stent were for LAD 6(30%), RCA 9 (45%), and
LCX 5 (25%).ER/Drug-eluting Stents S47
